Roxadustat Stacks Up To Darbepoietin In Non-Dialysis Anemia
Plus Positive CV Signals
Astellas’s oral HIF-PH inhibitor shows non-inferiority to one established ESA in head-to-head trial and while there were cardiovascular benefits, the picture is complex.
